Streetbeat News

Regulatory

EIS

SPY

USO

President Biden has announced that at least 11 American citizens were among those killed in Israel, and it is likely that American citizens may be among those being held by Hamas.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:19 pm

HARP

Harpoon Therapeutics is set to present interim tolerability and response data from the Phase 1/2 clinical trial of T cell engager HPN328 at the ESMO Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:18 pm

SPY

A U.S. Aircraft Carrier Strike Group is set to arrive in Eastern Mediterranean waters very soon, according to a senior U.S. Defense official. The SPY ETF, which tracks the S&P 500, may be indirectly affected by this news due to potential geopolitical implications.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:09 pm

AKRO

Akero Therapeutics, Inc. (NASDAQ:AKRO) will present the topline week 36 results from its Phase 2b SYMMETRY study on October 10. The study evaluates the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). The results will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins, as well as safety and tolerability.

Portfolio Pulse from Happy Mohamed

October 09, 2023 | 8:09 pm

MDRX

Veradigm Inc. (NASDAQ:MDRX) has received an extension on the temporary stay of delisting of its common stock from Nasdaq, pending a hearing on November 16, 2023. The company had previously received a delisting notice due to noncompliance with Nasdaq Listing Rule 5250(c)(1) for not filing its Annual Report and Quarterly Reports on time. The delay in filing is due to internal control failures primarily from accounting processes and a software tool implemented to comply with FASB's rule ASC 606.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:05 pm

LXRX

Lexicon Pharmaceuticals' heart failure treatment, INPEFA, has been approved by the FDA and will be listed as a preferred product on Express Scripts' Medicare national formularies from November 1, 2023. This will provide access to INPEFA for Express Scripts Medicare patients who meet the parameters of INPEFA's FDA-approved indication.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:03 pm

IMUX

Immunic has reported interim data from its Phase 2 CALLIPER trial of Vidofludimus Calcium in progressive multiple sclerosis. The 24-week data shows improvements in biomarker NfL across the overall patient population and all subtypes. The data also reinforces Vidofludimus Calcium's neuroprotective potential. Full brain volume data from the 467 patient cohort is expected in April 2025. The Phase 3 ENSURE program in relapsing multiple sclerosis is ongoing.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:02 pm

VTYX

Ventyx Biosciences announced positive results from its Phase 2 trial of VTX002. The drug achieved its primary endpoint of clinical remission with a high rate of complete endoscopic remission.

Portfolio Pulse from Bill Haddad

October 09, 2023 | 8:02 pm

EIS

SPY

USO

A senior U.S. Defense official has stated that the U.S. currently has no information to corroborate specific allegations of Iran's involvement in Hamas attacks in Israel, as reported by WSJ.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 7:55 pm

EIS

SPY

USO

VGK

A senior U.S. Defense official has stated that the U.S. military can provide support to both Israel and Ukraine while ensuring U.S. military readiness.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 7:49 pm